Testing a tool to measure liver inflammation in NAFLD
Part of Digestive system clinical trials.
This trial studies a device called LivQ-box to see if it can accurately measure liver inflammation in people with nonalcoholic fatty liver disease (NAFLD). It compares the device's results to a liver biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with nonalcoholic fatty liver disease (NAFLD).
- You are at least 18 years old.
- You do not have other liver diseases, such as hepatitis, drug-induced liver injury, or autoimmune liver disease.
- You are willing to have a special liver exam (iLivTouch) within 2 weeks of a standard liver biopsy.
- You do not drink more than 1 drink per day (women) or 2 drinks per day (men).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new scoring method can help doctors identify liver inflammation in patients who have both type 2 diabetes and a fatty liver. The goal is to find an easier, safer way to assess liver health without invasive procedures.
This study tests a new device called LiverScope® that scans your liver to detect fatty liver disease (MASLD). The scan uses special imaging technology and may help doctors diagnose liver disease more quickly and accurately.
This study compares two non-invasive approaches to diagnose advanced liver scarring in people with non-alcohol-related fatty liver disease (NAFLD). It may help confirm which test strategy finds advanced scarring without needing a biopsy for everyone.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study looks at how the liver's immune environment changes in people with non-alcoholic fatty liver disease (NAFLD) that has progressed to significant scarring. Researchers will use a liver biopsy to understand the inflammation better, which may lead to new treatments.
Hear when a new Liver Inflammation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.